Despite “ethical questions,” Secretary of Education Betsy DeVos continues to invest money in the scientifically dubious company Neurocore, according to Education Week.
In an August 7 report, Education Week reported that DeVos has “significantly increased her family’s financial stake” in the “brain performance” company Neurocore, which “makes questionable claims” about its ability to treat a number of neurological conditions in children and adults.
According to Education Week, there are several concerns surrounding DeVos’ increasing investment in Neurocore: “ethical questions” about potential conflicts of interest and “fresh worries from some researchers about DeVos’s commitment to rigorous scientific research.” From the August 7 report:
Neurocore purports to treat patients by analyzing their brainwaves and other biological signs, then providing “neurofeedback sessions” through which they can train their brains to function better. The company often uses such treatments with both adults and children. It charges as much as $2,200 for a 30-session cycle.
Overall, the evidence base for neurofeedback is weak, experts say.
Still, Neurocore has claimed that its technology can “fix” problems such as attention-deficit hyperactivity disorder and has “proven and long-lasting” positive effects on children with autism. In January, Education Week reported that the American Academy of Pediatrics and leading researchers all said there was limited evidence to support such assertions.
Now, the company is touting new research on its website. In a March press release, for example, Neurocore CEO Mark Murrison said a recently published study showed that Neurocore’s technology is a “viable treatment option for people dealing with anxiety or depression.”
Three experts consulted by Education Week all questioned the legitimacy of such claims, citing serious flaws with the study’s design that prevented it from generating credible evidence.
“They’re misleading, at best,” said Rebecca A. Maynard, a professor of education and social policy at the University of Pennsylvania’s Graduate School of Education.
“It bothers me to see anyone misusing evidence and promoting things that mislead the public,” said Maynard, a former commissioner at the Institute of Education Sciences, the research arm of the federal education department that DeVos now heads.
Raising her financial stake in Neurocore does not cross any clear ethical lines, and federal ethics officials signed off on the moves, said Larry Noble, the senior director and general counsel at the Campaign Legal Center, a Washington nonprofit staffed by election-law experts who promote public participation in democratic processes.
But the transactions do raise some new ethical questions for DeVos and the public moving forward, Noble said.
“I would want to watch very carefully if there is anything the department of education is doing that one could argue is going to help that company,” he said. “Also, if she had any inside information about anything that could have influenced the value of that stock, and she increased her holdings because of that, it would be a problem.”